While spinal muscular atrophy (SMA) affects individuals of all ages, it is usually first diagnosed in infants or children. There are multiple treatments for SMA approved by the U.S. Food and Drug Administration (FDA) and many other treatments being tested in clinical trials. This means that individuals with SMA and their families can choose the course of care and treatment that best fits their needs, goals, and values.
We acknowledge that it can be overwhelming to learn about and understand your options, especially when you are already overwhelmed with news of the diagnosis. However, research consistently shows that the earlier treatment can begin, the better. For babies who are identified through newborn screening, this means beginning treatment even before the baby shows symptoms of SMA.
It is important to contact your doctor or other healthcare provider immediately and learn about your options. We realize it can be a challenge to act fast, perhaps before you fully understand your child’s illness. But your child’s health depends on it.